Forest Laboratories Inc and Gedeon Richter announce results from a Phase II study of radiprodil for the treatment of diabetic peripheral neuropathic pain.

Forest Laboratories Inc and Gedeon Richter Plc announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP). Treatment with radiprodil did not show statistically significant or clinically meaningful reductions in mean daily pain scores, the primary endpoint, compared to placebo for any of the dosages studied. The companies will review the complete study database over the coming weeks to determine the …